Skip to main content

Table 2a Characteristics of the included studies (n = 21)

From: Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries

Study characteristics n (%) References
Country
 France 2 (10%) [38, 39]
 Germany 15 (71%) [18,19,20,21,22, 30, 37, 41,42,43, 45,46,47,48,49]
 Italy 2 (10%) [17, 40]
 Netherlands 2 (10%) [36, 44]
Publication year
 2015–2019 8 (35%) [17,18,19,20,21,22, 45, 49]
 2009–2014 11 (52%) [30, 40,41,42,43,44] [37, 39, 46,47,48]
  ≤ 2008 2 (10%) [36, 38]
Study design
 Non-controlled before-after study 3 (14%) [21, 38, 40]
 Retrospective cohort study 18 (86%) [17,18,19,20, 22, 30, 36, 37, 39, 41,42,43,44,45,46,47,48,49]
Guideline scope
 Diagnosis 2 (10%) [17, 40]
 Follow-up 1 (5%) [38]
 Treatment 20 (95%) [17,18,19,20,21,22, 30, 36, 37, 39,40,41,42,43,44,45,46,47,48,49]
Outcomes‡
 Overall survival 18 (86%) [12,13,14,15,16,17, 24,25,26,27, 29, 31,32,33,34,35,36,37, 49]
 Disease free survival 16 (76%) [13,14,15, 17, 24, 26, 28, 29, 31,32,33,34,35,36,37, 49]
 Costs associated to CGs adherence 2 (10%) [38, 39]
 Quality of life 0 (0%)
 Incidence-based mortality 0 (0%)
 Harm 0 (0%)
Risk of bias
 Low 17 (81%) [17, 20,21,22, 36, 37, 39,40,41,42,43,44, 46,47,48,49]
 Moderate 4 (20%) [18, 19, 38, 45]
 High 0 (0%)
  1. ‡ Percentages exceed 100% because the categories are not mutually exclusive (i.e. some studies involved more than one type of guideline and more than one type of outcome)